In this study of patients with metastatic MCC receiving the PD-1 blocking agent pembrolizumab [11], we have taken advantage of the unique viral etiology of most MCCs to explore MCPyV-specific humoral and cellular immune responses as an indicator of antitumor immunity. This evidence concerns the gene PDCD1 and Merkel cell skin cancer.